Ernesto Wasserman

Ernesto Wasserman, M.D. has served company since December 2016, first as Vice President of Clinical Development and currently as Senior Vice President of Clinical Development since January 2022. His responsibilities include overseeing the planning and executing of clinical programs from early stage through to potential registration. He has over 20 years of experience in oncology clinical drug development. Prior to joining Merus, Dr. Wasserman held positions of increasing responsibility at Novartis, leading development of early and late stage small molecules and biologics in oncology. Notably, he played a key role in the execution of a pivotal clinical program in metastatic melanoma leading to regulatory approval of Braftovi and Mektovi, and contributing to the clinical strategy for Novartis’ immuno-oncology portfolio. Dr. Wasserman is a board certified oncologist; he received his M.D. from the University of Buenos Aires, completed a fellowship in medical oncology at Hopital Paul Brousse (Paris) and visiting fellowships at Hospital 12 de Octubre (Madrid), Memorial Sloan Kettering (New York), and the National Cancer Center (Japan).